Lyell Immunopharma
Jessica Barragan has a diverse work experience in the field of research. Jessica is currently working as a Researcher at Lyell Immunopharma since March 2020. Prior to this, from August 2018 to March 2020, they served as a Staff Research Associate at UCSF Medical Center, where they worked on engineering regulatory T cells for rheumatoid arthritis. Jessica also worked as a Research Associate at Harvard Medical School/Boston Children's Hospital, mentored by George Q. Daley, M.D., from May 2015 to August 2018. Their earliest work experience was as an Undergraduate Research Assistant at Smith College, under the mentorship of Michael J. Barresi, Ph.D., from an unspecified start date to 2015.
Jessica Barragan obtained their Bachelor's degree in Biology/Biological Sciences, General from Smith College, where they attended from 2011 to 2015.
Lyell Immunopharma
Lyell is an immuno-oncology company dedicated to reprogramming T cells to achieve curative therapies for solid tumors. The company takes a deliberate approach to solving what it believes to be the major barriers to successful adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is combining its proprietary ex vivo genetic and epigenetic reprogramming technologies that address these barriers with T cell receptors (TCRs), tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptors (CARs).